Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic and guttate psoriasis)

Drug induced psoriasis

Use of other psoriasis treatments during the study

Prior use of etanercept

Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or the IL-17 receptor

Pregnant or lactating women; women who do not agree to use contraception during the study and for 16 weeks after stopping treatment

Significant medical problems such as uncontrolled high blood pressure, congestive heart failure, etc.

History of an ongoing, chronic or recurrent infection or evidence of tuberculosis

Allergy to rubber or latex

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis